The efficacy of short-term administration of 3 antihistamines vs placebo under natural exposure to Japanese cedar pollen

Annals of Allergy, Asthma and Immunology

Volumn 94, Issue 4, 2005, Pages 457-464

  Hyo, Sawako ^a,d   Fujieda, Shigeharu ^b   Kawada, Ryo ^a   Kitazawa, Shikifumi ^c   Takenaka, Hiroshi ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b UNIVERSITY OF FUKUI   (Japan)

^c NIHON UNIVERSITY   (Japan)

^d NONE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CETIRIZINE; FEXOFENADINE; LORATADINE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NOSE OBSTRUCTION; POLLEN; POLLEN ALLERGY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINOCONJUNCTIVITIS; SCORING SYSTEM; SYMPTOM; TREATMENT OUTCOME;

EID: 17444417420     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61116-7     Document Type: Article

References (36)

1. Okuda M. Epidemiology of Japanese cedar pollinosis throughout Japan. Ann Allergy Asthma Immunol. 2003;91:288-296.
2. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 1991;21:77-83.
3. Bousquet J, Bullinger M, Fayol C, et al. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J Allergy Clin Immunol. 1994;94:182-188.
4. Juniper EF, Guyatt GH, Griffith LE, et al. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol. 1996;98:843-845.
5. Leynaert B, Neukirch C, Liard R, et al. Quality of life in allergic rhinitis and asthma. Am J Respir Crit Care Med. 2000;162:1391-1396.
6. Noonan MJ, Raphael GD, Nayak A, et al. The health-related quality of life effects of once-daily cetirizine HCl in patients with seasonal allergic rhinitis: a randomized double-blind, placebo-controlled trial. Clin Exp Allergy. 2003;33:351-358.
7. Okuda M, Okubo K, Goto J, et al. Japanese version Rhinoconjunctivitis Quality of Life Questionnaire for Japanese cedar pollinosis. Jpn J Allergy. 2003;52:21-56.
8. Fujieda S, Noda I, Sugimoto C, et al. Effect of pretreatment with ketotifen on pollinosis: correlation with eosinophil cationic protein. Am J Rhinol. 1994;8:49-53.
9. 1 antihistamines. Int J Clin Pharmacol Ther. 1998;36:292-300.
10. Meltzer EO, Weiler JM, Widlitz MD. Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis. J Allergy Clin Immunol. 1996;97:617-626.
11. Day JH, Briscoe MP, Clark RH, et al. Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis. Ann Allergy Asthma Immunol. 1997;79:163-172.
12. Bernstein DI, Schoenwetter WF, Nathan RA, et al. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 1997;79:443-448.
13. Kaiser HB, Capano D, Harris A, et al. A double-blind, placebo-controlled comparison of the safety and efficacy of loratadine (Claritin), fexofenadine HCl (Allegro), and placebo in the treatment of subjects with seasonal allergic rhinitis. Allergy. 1999;52:322.
14. Van Cauwenberge P, Juniper EF. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy. 2000;30:891-899.
15. 1 antagonist, modulates RANTES and MCP-1 levels in allergic rhinitis. Int J Immunopathol Pharmacol. 2002;15:113-118.
16. Ciprandi G, Buscaglia S, Pesce G, et al. Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge. Allergy Clin Immunol. 1995;95:612-621.
17. Thomson L, Blaylock MG, Sexton DW, et al. Cetirizine and levocetirizine inhibit eotaxin-induced eosinophil transendothelial migration through human dermal or lung microvascular endothelial cells. Clin Exp Allergy. 2002;32:1187-1192.
18. Jin HR, Okamoto Y, Matsuzaki Z, et al. Cetirizine decreases interleukin-4, interleukin-5, and interferon-γ gene expressions in nasal-associated lymphoid tissue of sensitized mice. Am J Rhinol. 2002;16:43-48.
19. Vignola AM, Crampette L, Mondain M, et al. Inhibitory activity of loratadine and descarboethoxyloratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells. Allergy. 1995;50:200-203.
20. Paolieri F, Battifora M, Riccio AM, et al. Terfenadine and fexofenadine reduce in vitro ICAM-1 expression on human continuous cell lines. Ann Allergy Asthma Immunol. 1998;81:601-607.
21. Campbell A, Chanal I, Czarlewski W, et al. Reduction of soluble ICAM-1 levels in nasal secretion by H1-blockers in seasonal allergic rhinitis. Allergy. 1997;52:1022-1025.
22. Abdelaziz MM, Devalia JL, Khair OA, et al. Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis. J Allergy Clin Immunol. 1998;101:410-420.
23. Asano K, Kanai K, Suzaki H. Suppressive activity of fexofenadine hydrochloride on thymus- and activation-regulated chemokine production from human peripheral blood leukocytes in response to antigenic stimulation in vitro. Int Arch Allergy Immunol. 2004;133:267-275.
24. Gelfand EW, Cui ZH, Takeda K, et al. Fexofenadine modulates T-cell function, preventing allergen-induced airway inflammation and hyper-responsiveness. J Allergy Clin Immunol. 2002;110:85-95.
25. Molet S, Gosset P, Lassalle P, et al. Inhibitory activity of loratadine and descarboxyethoxyloratadine on histamine-induced activation of endothelial cells. Clin Exp Allergy. 1997;27:1167-1174.
26. Bayram H, Devalia JL, Khair OA, et al. Effect of loratadine on nitrogen dioxide-induced changes in electrical resistance and release of inflammatory mediators from cultured human bronchial epithelial cells. J Allergy Clin Immunol. 1999;104:93-99.
27. Amsellem C, Czarlewski W, Lagarde M, et al. Inhibitory effect of loratadine on leukotriene B4 production by neutrophils either alone or during interaction with human airway epithelial cells. Pulm Pharmacol Ther. 1998;11:245-252.
28. Day JH, Briscoe M, Widlitz MD. Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit. J Allergy Clin Immunol. 1998;101:638-645.
29. Day JH, Briscoe M, Rafeiro E, et al. Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: confirmation of a test system. Ann Allergy Asthma Immunol. 2001;87:474-481.
30. Mansmann HC Jr, Altman RA, Berman BA, et al. Efficacy and safety of cetirizine therapy in perennial allergic rhinitis. Ann Allergy. 1992;68:348-353.
31. Lockey RF, Widlitz MD, Mitchell DQ, et al. Comparative study of cetirizine and terfenadine versus placebo in the symptomatic management of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 1996;76:448-454.
32. Murray JJ, Nathan RA, Bronsky EA, et al. Comprehensive evaluation of cetirizine in the management of seasonal allergic rhinitis: impact on symptoms, quality of life, productivity, and activity impairment. Allergy Asthma Proc. 2002;23:391-398.
33. Burtin B, Duchateau J, Pignat JC, et al. Further improvement of quality of life by cetirizine in perennial allergic rhinitis as a function of treatment duration. J Invest Allergol Clin Immunol. 2000;10:66-70.
34. Nunes C, Ladeira S. Double-blind study of cetirizine and loratadine versus placebo in patients with allergic rhinitis. J Invest Allergol Clin Immunol. 2000;10:20-23.
35. Howarth PH, Stern MA, Roi L, et al. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol. 1999;104:927-933.
36. Horak F, Stubner P, Zieglmayer R, et al. Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis. Int Arch Allergy Immunol. 2001;125:73-79.